Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease

Graphical abstract

[1]  Natalie J Torok,et al.  Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014 , 2015, Hepatology.

[2]  Fabio Nascimbeni,et al.  Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Mohammad Hassan Murad,et al.  Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  D. Brenner,et al.  Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial) , 2015, Hepatology.

[5]  Hiroshi Onishi,et al.  Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis. , 2015, Magnetic resonance imaging.

[6]  M. Bellis,et al.  Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis , 2014, The Lancet.

[7]  Ding‐Shinn Chen,et al.  Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new‐onset diabetes: A nationwide cohort study , 2014, Hepatology.

[8]  Julien Vergniol,et al.  Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan®. , 2014, Journal of hepatology.

[9]  A. Schreyer,et al.  MRI-based estimation of liver function: Gd-EOB-DTPA-enhanced T1 relaxometry of 3T vs. the MELD score , 2014, Scientific Reports.

[10]  R. Ehman,et al.  Role of magnetic resonance elastography in compensated and decompensated liver disease. , 2014, Journal of hepatology.

[11]  M. Robson,et al.  Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease , 2014, Journal of hepatology.

[12]  J. Stoker,et al.  Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C , 2014, European Radiology.

[13]  P. Bedossa,et al.  A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.

[14]  R. Levine,et al.  Wedge and needle liver biopsies show discordant histopathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery , 2013, Gastroenterology report.

[15]  Berthold Kiefer,et al.  Quantitative evaluation of liver cirrhosis using T1 relaxation time with 3 tesla MRI before and after oxygen inhalation , 2012, Journal of magnetic resonance imaging : JMRI.

[16]  H. Kauczor,et al.  MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis , 2012, European Radiology.

[17]  J. Vinel,et al.  Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. , 2011, Journal of hepatology.

[18]  Vincent Wai-Sun Wong,et al.  Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography , 2011, Gut.

[19]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[20]  Stefan Neubauer,et al.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[21]  Rajiv Mahajan,et al.  Food and drug administration’s critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies , 2010, Journal of pharmacy & bioallied sciences.

[22]  G. Alexander,et al.  Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease , 2010, Gut.

[23]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[24]  Scott B Reeder,et al.  Repeatability of magnetic resonance elastography for quantification of hepatic stiffness , 2010, Journal of magnetic resonance imaging : JMRI.

[25]  G. Marchesini,et al.  HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[26]  William M. Lee,et al.  Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long‐term treatment against cirrhosis (HALT‐C) trial , 2009, Hepatology.

[27]  D. Thabut,et al.  Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers , 2008, PloS one.

[28]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[29]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[30]  D. Schuppan,et al.  Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.

[31]  P. Prasad,et al.  Steatosis and fibrosis in patients with chronic hepatitis C , 2004, Journal of Clinical Pathology.

[32]  L. Braitman,et al.  The impact of diabetes and obesity on liver histology in patients with hepatitis C. , 2004, Diabetes, obesity & metabolism.

[33]  L. Braitman,et al.  The impact of diabetes and obesity on liver histology in patients with hepatitis C , 2003 .

[34]  J. Pawlotsky,et al.  Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies , 2003, Gut.

[35]  E. Jury.  EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). , 2003 .

[36]  E. Jury.  EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). , 2003, Journal of hepatology.

[37]  M. Ziol,et al.  Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study , 2000, Gut.

[38]  J. Goldin,et al.  Intra-observer variation in the histopathological assessment of chronic viral hepatitis , 1996 .

[39]  J. Goldin,et al.  Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. , 1996, Journal of hepatology.

[40]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .